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Abstract  
Natural killer (NK) cells were originally described in terms of their function. NK cells are of lymphoid origin 
and are found in the peripheral blood, spleen, and bone marrow, as well as other tissues. These cells are large, radio-
resistant and granular lymphocytes that represent an important arm of innate immunity and are thought to play a 
critical role in the immune surveillance against tumors and virally infected cells. Allogeneic bone marrow 
transplantation (BMT) has proven to be an effective treatment for hematologic malignancies and some solid tumors. 
One of the major challenges of allo-stem cell transplantation (SCT) is to reduce the incidence and severity of GVHD 
while boosting the graft-versus-leukemia (GVL) effect. In the setting of allo-SCT, the reconstitution of NK cells is 
of notable interest due to their known capability to induce GVL without GVHD. Clinical applications of NK cells 
have been inspired by recognition of their potent anticancer activity. These studies discussed a solid basis for 
development of future NK cell trials for cancer therapy by minimizing risks and toxicities. 
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Natural killer Cell Biology and 
Receptors 
 
In 1971 Natural killer (NK) cells were 
originally described in terms of their function. NK 
cells are of lymphoid origin and are found in the 
peripheral blood, spleen, and BM, as well as other 
tissues. These cells are large, radio-resistant and 
granular lymphocytes that represent an important arm 
of innate immunity and are thought to play a critical 
role in the immune surveillance against tumors and 
virally infected cells(1). 
Two major subsets of NK cells are found in 
human subjects that can be distinguished by their 
levels of CD56 expression, namely CD56dim and 
CD56bright(2). CD56dim NK cells are fully mature, 
make up approximately 90% of the NK cells in 
peripheral blood, and predominantly mediate 
cytotoxicity responses. In contrast, CD56bright cells 
are more immature, make up approximately 5% to 15% 
of total NK cells, and have been considered primarily 
as cytokine producers while playing a limited role in 
cytolytic responses(3). 
NK cells are regulated by a number of receptors 
with opposite function that finely tune potent effector 
functions such as cytolytic activity; through the 
perforin/granzyme-dependent pathway and use of Fas 
ligand (FasL) and tumor necrosis factor related 
apoptosis inducing ligand (TRAIL) to kill target cells; 
and production of cytokines playing a key role in 
inflammation and regulation of both innate and 
adaptive immune responses(4, 5). So cytokines play a 
major role in the differentiation (IL-15, fms-like 
tyrosine kinase 3(flt3) ligand, stem cell factor(SCF), 
fetal liver kinase ligand(flk2L)) and in the function (IL-
2, IL-15, IL-18, IL-21 and IFN-α/β) of NK cells(6, 7). 
Generally NK cells have 5 main categories of 
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cell surface receptors. Activating  receptors (e.g. 
CD16, NKp46, NKG2D, NKG2C, KIR-S, Ly9), 
inhibitory receptors (e.g. KIR-L, NKG2A), 
chemotactic receptors (e.g. CCR2, CCR5, CXCR1, 
CXCR4, CXCR6), cytokine receptors(e.g. IL-1R, IL-
15R, IL-18R), adhesion receptors(e.g. β1 integrins) 
(8).To explain more about the receptors of this 
intrinsic immune cell, here is a brief summary about 
them: An important category of receptors in the NK 
cells are the killer cell Ig-like receptors (KIRs) which 
specifically recognize groups of HLA-C, HLA-B and 
HLA-A alleles (9, 10). 
Another class of MHC class I-specific 
receptors is comprised of the C-type lectin molecule 
CD94, which is covalently associated with a member 
of the NKG2 family. Like KIR receptors, these 
receptors have been also shown to exert inhibitory 
(NKG2A or NKG2B) or activating (NKG2C) signals 
upon binding non-classical HLA-E molecules on 
human targets (11). NK cells also have Ig-like 
transcript (ILT) receptors that interact with HLA-G (to 
protect the fetus and placenta from rejection (12). 
Another group of NK cell receptors comes from a 
more diverse family of receptors of NK-cell-specific 
Ig-like molecules that are known as natural 
cytotoxicity receptors, or NCRs. NCRs include 
NKp30, NKp46, and NKp44 as well as NKG2D. 
NKG2D is a member of the NKG2 family expressed 
by NK cells and cytotoxic lymphocytes (CTLs) (13, 
14).Most NK cells can express the FcγRIII (CD16) 
molecule, which recognizes the Fc component of 
bound Ig molecules and initiates cytolysis by the 
antibody dependent cellular cytotoxicity (ADCC) 
pathway, thus giving the NK cell another method of 
target recognition(10, 15) 
Recently, NK cells were officially classified as 
the prototypical members of the group 1 innate 
lymphoid cells (ILCs), which are defined by their 
capacity to secrete IFN-Ƴ but not type 2 cytokines 
(IL-4 and IL-13), IL-17, or IL-22 (16). Human NK 
cells are classically defined as CD56+CD3- cells, 
distinguishing them from CD56+CD3+ cells, which 
consist of a mixed population of NK-like T cells and 
antigen-experienced T cells that have upregulated 
several NK cell markers(17). 
 
Natural killer Cell and GVHD 
 
Allogeneic bone marrow transplantation (BMT) 
has proven to be an effective treatment for hematologic 
malignancies and some solid tumors(18). However, the 
high incidence of graft-versus-host disease (GVHD) as 
a complication of this treatment has limited the overall 
effectiveness of BMT. GVHD is mediated by the 
activation and proliferation of alloreactive T cells and 
causes tissue damage in the host, primarily in the 
gastrointestinal tract, liver, and skin causing significant 
morbidity and mortality. 
One of the major challenges of allo-Stem Cell 
Transplantation (SCT) is to reduce the incidence and 
severity of GVHD while boosting the graft-versus-
leukemia (GVL) effect. In the setting of allo-SCT, the 
reconstitution of natural killer (NK) cells is of notable 
interest due to their known capability to induce GVL 
without GVHD. Studies of the role of NK cells in bone 
marrow engraftment demonstrated that host NK cells 
persisting after conditioning can contribute to graft 
rejection while donor NK cells can promote 
hematopoietic engraftment. 
The first study suggesting a relationship between 
NK cells and GvHD development was reported by 
Lopez and coworkers from the Sloan Kettering Cancer 
Center. They showed  a significant association between 
GvHD development and pre-transplant levels of NK 
cell activity, as measured by cytotoxic assays 
performed using herpes simplex virus type 1-infected 
fibroblast as target cells, in peripheral blood of a small 
and heterogeneous cohort of 13 patients undergoing 
different protocols of HCT(19). In 2015 Jacobs B. and 
et al could demonstrate that NK cells gain cytotoxic and 
cytokine producing functions early during 
hematopoietic immune reconstitution following 
autologous SCT.(5) In addition to clinical studies, it has 
been shown in animal models that IL-2-activated NK 
cells may efficiently prevent or even reduce GVHD 
without any adverse impact on their important GVL 
effect (20). 
After chemotherapy or hematopoietic stem cell 
transplantation, NK cells are the first lymphoid cells to 
recover(21). Surprisingly, such post grafting 
regeneration of NK cells does not cause clinical graft-
versus-host disease (GVHD); this has led to the 
conclusion that normal nonhematopoietic tissues lack 
ligands able to activate NK cell lysis(22). 
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The concept of an NK-mediated regulatory 
function is also supported by the observation that a 
higher number of bone marrow NK cells has been 
associated with a decreased incidence of chronic 
GVHD after HLA identical sibling bone marrow 
transplants in human(23). Researches in 2002 and 
2004 showed that this regulatory function can be 
indirect, through the interplay and molecular crosstalk 
with dendritic cells (DCs) (24, 25). On the one hand, 
DCs can prime, further the activation of, augment the 
expansion of, and enhance the activities of NK cells 
through the production of cytokines such as IL-2, IL-
12, IL-15, IFN-a/b, and TNFa(26).The regulatory 
function of NK cells on adaptive immune responses 
appears also to be mediated through direct lysis of 
activated T cells(27, 28).This pathway has been 
postulated to play an important role in the generation 
of memory T cell repertoire. Several recent 
observations suggest that certain subpopulations of 
NK cells promote allograft tolerance via a cytolysis-
dependent regulatory pathway(29). However, little is 
known about the effects of NK cells on donor T cells 
after BMT. In 2010, it was shown  that NK cells can 
regulate chronic GVHD by limiting recipient minor 
histocompatibility Ag (mHA)-driven proliferation of 
donor CD4+ T cells(30). 
According to studies by scientists, the 
relationship between NK cell and GVHD can be 
generally described in two ways: firstly, NK Cell 
cytotoxic functions and GvHD prevention: NK cells 
can suppress GvHD development through their 
cytotoxic function either directly, by depleting 
activated alloreactive T cells, or indirectly, by 
depleting APC and preventing T cell stimulation cell 
killing by NK cells appears to be dependent on both 
perforin production  and FAS-mediated induction of 
apoptosis, and secondary NK cell cytokine production 
and GvHD induction, Although it is unclear if NK 
cells production of immunesuppressive cytokines can 
prevent GvHD(4, 31),it is established that pro-
inflammatory cytokine production by NK cells can 
contribute to GvHD development(32).In a xenogeneic 
model, Xun et al. showed that in vitro interleukin-2 
(IL-2)-activated human NK cells producing 
interferon-γ(IFN-γ) and tumor necrosis factor-α(TNF-
α) were able to induce acute GVHD upon transfer into 
SCID mice .What is now important about NK cells 
and its impact on GVHD is that researchers are looking 
for new ways to reduce GVHD with the help of these 
cells, which we will continue to mention these 
activities(33). 
 
Natural Killer Cell Memory 
 
The ability of the immune system to respond 
rapidly and provide enhanced protection of the host 
against a previously encountered pathogen is defined 
classically as immunological memory. Immunological 
memory is a cardinal feature of adaptive immunity. 
Although NK cells have long been considered short-
lived innate lymphocytes that respond rapidly to 
transformed and virus-infected cells without prior 
sensitization, it has recently become appreciated that 
NK cells can also acquire functional qualities 
commonly associated with immunological memory 
similar to that of T and B cells in response to pathogens 
and in non-infectious settings(34). 
Antigen-specific memory NK cell responses 
were first observed in a murine model of hapten-
induced CHS(35). 
Long lived memory cells are generated after 
initial infection and display heightened responses upon 
secondary challenge with the same pathogen. The 
process of memory formation in T cells has been well 
studied and is generally divided into three distinct 
phases. Upon exposure to cognate antigen, naive CD8+ 
T cells clonally expand and differentiate into effector 
cells during the ‘‘expansion’’ phase. This first phase is 
followed by a rapid ‘‘contraction’’ phase, when the vast 
majority of effector CD8+ T cells undergo apoptosis to 
form a small, but stable, pool of surviving cells that then 
enter the third ‘‘memory’’ phase. Memory CD8+ T 
cells persist throughout the host organs and maintain 
their longevity through self-renewal until a subsequent 
encounter with their cognate antigen, when they exhibit 
enhanced effector function and host protection. In an 
experimental system in which Ly49H+ NK cells were 
adoptively transferred into mice lacking this receptor, 
these Ly49H+ cells underwent robust antigen-driven 
expansion after MCMV infection. Similar to activated 
CD4+ T cells, expanded effector NK cells undergo a 
slower and sustained contraction phase to establish a 
long-lived and self-renewing ‘‘memory’’ pool of 
antigen-specific NK cells that can be recovered many 
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months after infection in a variety of peripheral 
tissues(36). 
CAR modified Natural killer cells 
 
Recent years have seen remarkable advances in 
field of engineering of immune cells as cancer 
therapy. Whereas chimeric antigen receptors (CARs) 
have been used comprehensively to convey the 
specificity of autologous T cells against hematological 
malignancies with remarkable clinical results, studies 
of CAR-modified natural killer cells have been 
generally in preclinical phases(37). NK cells for 
adoptive therapy can be derived from several different 
sources which is explained in other parts. Allogeneic 
NK cells can be generated from the peripheral blood 
of healthy donors or expanded from umbilical cord 
blood. Regardless of the source, there are several 
features of expanded, activated CB, or PB-derived NK 
cells that make them useful effectors for gene 
modification. 
With CAR-modified primary human NK cells 
can be effector modified immune cells against a 
number of hematologic and solid tumor antigens, 
including CD19, CD20, GD2, and HER-2(38-40). 
While non-viral expression techniques such as 
nucleofection or electroporation can produce robust 
CAR-mediated killing, the short-lived nature of these 
CAR molecules would likely dictate the need for 




Expanded, activated NK cells generally express 
a wide range of activating receptors, including CD16, 
NKG2D, and the NCRs (NKp44 and NKp46), in spite 
of donor-to-donor variability(42, 43). These activated 
NK cells are prepared with KIRs and are “licensed to 
kill.” In vivo expansion and persistence capacity of 
NK cells is clearly associated with antitumor activity 
in trials involving hematologic malignancies such as 
AML(44, 45). Moreover, ex vivo expanded primary 
human NK cells produce a different storm of 
cytokines more than T cells, including interferon 
(IFN)-g, IL-3, and granulocyte macrophage colony-
stimulating factor (GM CSF), which may be 
associated with a lower risk of CRS(cytokine released 
syndrome) 
While normal NK cell counts are usually 
detected within the first month after alloSCT regardless 
of the graft source, several months are required to 
acquire the immunophenotypic and functional 
characteristics of NK cells found in healthy donors. 
Rebuilding NK cells display a more immature 
phenotype expressing the inhibitory natural killer group 
two A (NKG2A) receptor at around 90% compared to 
around 50% in healthy donors. During the NK 
development and peripheral maturation, the CD56dim 
NK cells lose NKG2A expression but up-regulate the 
expression of the activating NKG2C receptor, killer cell 
inhibitory immunoglobulin-like receptors (KIRs) and 
CD57(46). The allo reactivity of NK cells is determined 
by various receptors including the activating 
CD94/NKG2C and the inhibitory CD94/NKG2A 
receptors, which both recognize the non-classical 
human leukocyte antigen E (HLA-E. studies have 
shown that NK cells expressing the activating 
CD94/NKG2C receptor are significantly reduced in 
patients after alloSCT with severe acute and chronic 
graft-versus-host disease (GvHD). Moreover, the ratio 
of CD94/NKG2C to CD94/NKG2A was reduced in 
patients with severe acute and chronic GvHD after 
receiving an HLA-mismatched graft. Collectively, 
these results provide evidence for the first time that 
CD94/NKG2C is involved in GvHD prevention(12). 
 
IL2 and LAK cells, a key for more 
and powerful NK cells  
 
At the University of Minnesota, researchers first 
confirmed the daily use of low dose IL-2 to expand NK 
cells after autologous HSCT in patients with non-
Hodgkin lymphoma and breast cancer. Later, they 
activated autologous NK cells ex vivo with IL-2 for 24 
hours, infused them into patients and administered 
subcutaneous IL-2 on daily basis .While autologous NK 
cell studies showed limited efficacy, they did yield 
important findings: 1).IL-2 can be administered safely 
at daily or 3 times weekly intervals, 2) IL-2 can induce 
an increase in circulating cytotoxic lymphocytes with a 
disproportionate increase in NK cells(47). 
In innovative studies at the NCI, Rosenberg and 
colleagues infused melanoma and renal cell carcinoma 
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patients with autologous peripheral blood cells treated 
ex vivo with IL-2. The product was enriched with NK 
cells and named “lymphocyte activated killer” (LAK) 
cells. High dose IL-2 was administered to patients 
after LAK infusions to promote their in vivo 
persistence and activity. In a subsequent trial, the NCI 
group adoptively transferred in vitro expanded 
autologous tumor-infiltrating lymphocytes (TILs) to 
patients with metastatic melanoma(48). These studies 
and others have revealed  important new knowledge: 
1) high-dose IL-2 used in vivo with the goal of 
activating NK cells has significant but manageable 
toxicity owing to severe capillary leak syndrome, 
whereas low-dose subcutaneous IL-2 was well 
tolerated, 2) lymphodepleting chemotherapy using 
high-dose cyclophosphamide and fludarabine 
facilitated in vivo expansion of autologous adoptively 
transferred cytotoxic T lymphocytes and led to 
enhanced efficacy,3) chemotherapy induces 
lymphopenia, changes the competitive balance 
between transferred lymphocytes and endogenous 
lymphocytes, changes the cytokine milieu and 
depletes inhibitory cell populations (T regulatory cells 
[Tregs])(49). 
 
MSC and Natural killer cell 
therapy 
 
Bone-marrow-derived MSCs (BM-MSCs) can 
inhibit NK cell proliferation, cytotoxicity, and 
cytokine production by secreting IDO1, TGFb, HLA-
G, and PGE2(50, 51).However, they can be also  lysed 
by activated NK cells, depending on their expression 
of activating NK receptor ligands, including MHC 
class I polypeptide-related sequence (MICA, B), 
UL16 binding proteins (ULBPs), CD112, and CD155. 
Mesenchymal stem cells (MSCs) show 
pleiotropic factors with immunosuppressive activity 
involved in cancer progression(52, 53). This is 
observed that T cell derived MSCs were more 
powerfully immunosuppressive than NK-MSCs and 
affected both NK function and phenotype by CD56 
expression. T-MSCs shifted NK cells toward the 
CD56dim phenotype and differentially modulated 
CD56bright/dim subset functions. However MSCs 
affected both degranulation and activating receptor 
expression in the CD56dim subset, they mainly 
inhibited interferon-gamma production in the 
CD56bright subset. Pharmacological inhibition of 
prostaglandin E2 (PGE2) synthesis and, in some MSCs, 
interleukin-6 (IL-6) activity restored NK function, 
whereas NK cell stimulation by PGE2 alone mirrored 
T-MSC-mediated immunosuppression. Our 
observations provide insight into how stromal 
responses to cancer reduce NK cell activity in cancer 
progression[53]. 
The spectrum of MSC immunosuppressive 
activity in humans includes secretion of human 
leukocyte antigen (HLA-G), transforming growth 
factor b (TGFb), prostaglandin E2 (PGE2), tumor 
necrosis factor alpha-inducible protein 6 (TNFAIP6/ 
TSG-6), heme oxygenase 1 (HO-1/HMOX1), IL-10, 
IL-6, indoleamine 2,3-dioxygenase 1 (IDO1), 
hepatocyte growth factor (HGF), and leukemia 
inhibitory factor (LIF) as well as programmed death 
ligand (PD-L1/2) and Fas ligand (FasL) signaling(54-
56). 
The finding that MSCs could inhibit the 
expression of activating receptors on the surface of NK 
cells was indicative of a possible loss of cytotoxic 
activity known to involve engagement of causing 
receptors. To assess a possible MSC-mediated 
inhibitory effect on the lytic potential of NK cells, 
researchers did cytolytic assays in different NK-cell 
populations from different donors were used as 
effectors after short-term culture with 100 U/mL IL-2 
either in the presence or in the absence of MSCs(57).  
MSCs were originally shown to have strong 
inhibitory effect on T-cell activation and function. In 
recent years, inhibition has been also observed in 
dendritic cells (DCs), B cells, and NK cells. In this 
framework, researchers informed that MSCs can block 
the IL-2–induced proliferation of fresh peripheral blood 
NK cells. The use of MSCs may become a common 
approach in BM transplantation not only for their 
possible beneficial effect on the engraftment of 
hematopoietic stem cells, but also for their 
immunosuppressive potential. On the other hand, NK 
cells have been shown to play a central role in the 
successful outcome of haplo identical BM 
transplantation to treat AML.NK cells derived from the 
HSCs of the donor can exert a direct GVL effect, 
provided they express KIRs that do not recognize one 
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or more HLA class I alleles of the patient.  
Recent studies reported that NK-MSC 
interactions not only provided strong MSC-mediated 
anti proliferative effect on NK cells but also verified 
that IL-2–activated NK cells can powerfully kill both 
allogeneic and autologous MSCs. The killing reflects 
the fact that MSCs are characterized by low levels of 
HLA class I antigens and also express several ligands 




1. Genetic modification and alternative sources 
of NK cell products 
To overcome restrictions of the donor-derived 
NK cell therapies, several groups have investigated 
alternative donor sources including UCB, NK cell 
lines and pluripotent stem cells. If cryopreservation 
can be optimized, the quick availability of an off-the-
shelf product denotes a significant step forward. 
Further advantages include the ability to perform 
preclinical testing and to select for donors based on 
favorable characteristics including optimal KIR-
genotype(59). 
2. UCB-derived NK cells 
UCB progenitors provide a rich source of 
hematopoietic progenitor cells and serve as an 
important in vitro system for studying the 
development of human NK cells. Clinically 
appropriate doses of UCB-derived NK cells can be 
generated without the use of feeder cells in compare 
to NK cells derived from peripheral blood(59) . NK 
cells generated from UCB contain a mixture of 
immature and mature cells that produce cytokines and 
show cytotoxicity. Development of functional NK 
cells (e.g. CD34 isolation, in vitro expansion) takes up 
to 4 weeks and requires processing in a GMP facility. 
Studies are incomplete and preliminary data is 
insufficient to assess comparative advantages(60).  
3. NK cell lines 
Many research teams have explored the use of 
cell lines derived from malignant NK cell clones ( NK-
92, NKL, KYHG-1, YT, NKG) NK cell lines keep 
some level of direct cytotoxic function and usually 
lack expression of inhibitory KIR. Because they can 
be grown in culture, genetic modification with 
different cytokine genes or chimeric antigen receptors 
is easily accomplished. Among the lines, NK-92 cells 
remain the most established and have been tested in 
clinical trials that include patients with renal cell 
carcinoma and malignant hematological malignancies. 
. Because of their amenability to ex vivo manipulation, 
these cell lines may provide an important platform to 
facilitate whole-body in vivo imaging of infused cells. 
Appropriate technology remains to be developed(59). 
4. NK cells derived from pluripotent stem cells 
Pluripotent stem cells are as an available and 
additional source of NK cells. These include human 
embryonic stem cells (hESCs) and induced pluripotent 
stem cells (iPSCs). Novel methods of iPSC generation 
have approached 100% efficiency, thus bringing closer 
the day that hematopoietic-based therapies derived 
from these lines become available for clinical use. A 
defined method for producing NK cells from hESCs 
and iPSCs amenable to clinical translation has been 
recently established [62]. By adapting a feeder-free 
differentiation system, mature and functional NK cells 
can be generated in a system agreeable to clinical scale-
up. Significantly, in contrast to UCB-CD34+ derived 
NK cells or NK cell lines, the iPSC-derived NK cells 
maintained high levels of KIR and CD16 expression. If 
KIR expression does indeed dictate acquisition of final 
effector function, some of the relative advantages of 
using iPSC-derived NK cells for anti-cancer therapies 
are clarified. Using this improved differentiation 
method, it is estimated that one 6-well plate of hESCs 
or iPSCs could provide enough NK cells to treat several 
patients at the PB-NK doses currently used. Other 
advantages are:  
1) Unlimited source of KIR-typed NK cells for 
adoptive immunotherapy,  
2) High level of function in preclinical animal 
models  
3) A platform genetically responsive to modify 
the therapy based on the patient’s cancer via tumor-
specific receptors (TCRs or CARs)(61).  
At present, however, using iPSCs on a patient-
specific basis is impossible. Third party iPSC-derived 
NK cells are subject to immune rejection in the 
recipient. To circumvent this limitation, specific 
genetic modulation must be used to decrease 
immunoreactivity of the infused cells(61). 
 
Conclusion 
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Clinical applications of NK cells has been 
inspired by recognition of their potent anticancer 
activity. These studies discussed a solid basis for 
development of future NK cell trials for cancer 
therapy by minimizing risks and toxicities. Important 
questions remain to be answered, most urgently, 
determination of minimum in vivo NK cell expansion 
needed for effective anti-tumor activity in clinical 
approaches. At present, results involving NK cell 
expansion interventions remain capricious. Also, NK 
therapy for solid tumors is limited by uncertain 
homing which its mechanism is unknown and have 
autoimmune diseases by an immunosuppressive 
induced microenvironment that may interfere with 
immune responses. To improve and progress NK cell 
therapies, both further study of basic NK biology and 
a better understanding of interactions with other 
immune cells will be required. NK cell products 
characteristics and effective cytokine cocktails with 
optimal proportions will probably differ from different 
tumor types and patients. Targeting CD16 remains an 
attractive way to increase specificity, resembling of 
genetically modified T cells. Future clinical trials will 
be designed to exploit strategies to overcome the host 
immune barriers. In the same way, strategies to 
discover ex vivo NK cell expansion from blood, 
lymphoid progenitors, or other sources are being 
tested. In hematopoetic stem cell transplantation, 
future studies are evaluating donor NK cell 
immunogenetics.  
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